Related Announcements

RFA-AT-22-004 - HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional)

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

This Notice updates the NHLBI-specific areas of interest in Funding Opportunity Announcement (FOA) RFA-AT-22-004, "HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional)".

The following sections of RFA-AT-22-004 has been modified as follows:

Currently Reads:

Part 2. Full Text of Announcement
Section I. Funding Opportunity Description

IC-Specific Areas of Interest

National Heart, Lung, and Blood Institute (NHLBI)

The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership in research, training, and education programs to promote the prevention and treatment of heart, lung, and blood diseases and sleep disorders (HLBS). The acute and chronic pain of sickle cell disease are major sources of decreased quality of life and are poorly responsive to current therapeutic modalities. Multi-site clinical trials that are of interest will evaluate the effectiveness of approaches that are informed by the bio-psychosocial model of pain management utilizing multi-disciplinary combinations of behavioral, pharmaceutical, interventional, and rehabilitative modalities to address the co-morbidities often present in patients with pain associated with SCD. While several studies have shown that the incidence of opioid addiction in SCD is low, the prolonged use of often high-dose daily oral opioid medications leads to dependence, risk of overdose, respiratory depression, immune dysfunction and hyperalgesia and has not been shown to be a highly effective treatment for chronic pain. Trials that evaluate the effectiveness of coordinated, multidisciplinary management strategies that reduce acute and/or chronic SCD pain and that, while continuing to provide access to opioid pain management when needed, can reduce or eliminate daily opioid use will also be of interest.

Scientific/Research Contact(s)

Susan Shero
National Heart, Lung, And Blood Institute (NHLBI)
Phone: none
E-mail: ss632e@nih.gov

Modified to Read (changes shown in bold italics):

Part 2. Full Text of Announcement
Section I. Funding Opportunity Description

IC-Specific Areas of Interest

National Heart, Lung, and Blood Institute (NHLBI)

The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership in research, training, and education programs to promote the prevention and treatment of heart, lung, and blood diseases and sleep disorders (HLBS). NHLBI seeks to optimize clinical and implementation research to improve health and reduce disease. In the context of this FOA, NHLBI is interested in studies of effective strategies to train primary care providers, nurse practitioners and patient care navigators in sickle cell disease pain management, and to incorporate technology (e.g., telemedicine) to extend care by specialists to providers in the community; investigations that use implementation strategies to facilitate care transitions, such as from inpatient to outpatient, or pediatric to adult, to maintain optimal evidence-based SCD pain management care; research on reducing or stopping (de-implementing) the use of HLBS clinical and community practices that are ineffective, unproven, low-value, or harmful; research that focuses on clinical decision support systems to facilitate shared decision-making approaches in clinical and community settings; research on how best to integrate evidence-based interventions across diverse populations and clinical settings that take into account social determinants of health; and studies testing the effectiveness and cost-effectiveness of dissemination or implementation strategies to reduce health disparities and improve health care and quality of life among rural, minority, low literacy and numeracy, and other disproportionately affected populations.

Scientific/Research Contact(s)

Susan Shero
National Heart, Lung, And Blood Institute (NHLBI)
Phone: 301-496-1051
E-mail: ss632e@nih.gov

All other aspects of the FOA remain the same.

Inquiries

Please direct all inquiries to:

Susan Shero
National Heart, Lung, And Blood Institute (NHLBI)
Phone: 301-496-1051
E-mail: ss632e@nih.gov